Gain Therapeutics (GANX) Debt to Equity (2020 - 2025)
Historic Debt to Equity for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $0.07.
- Gain Therapeutics' Debt to Equity rose 2939.9% to $0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.07, marking a year-over-year increase of 2939.9%. This contributed to the annual value of $0.06 for FY2024, which is 3233.92% up from last year.
- According to the latest figures from Q3 2025, Gain Therapeutics' Debt to Equity is $0.07, which was up 2939.9% from $0.12 recorded in Q2 2025.
- In the past 5 years, Gain Therapeutics' Debt to Equity registered a high of $0.12 during Q2 2025, and its lowest value of $0.02 during Q1 2021.
- Moreover, its 5-year median value for Debt to Equity was $0.04 (2024), whereas its average is $0.05.
- Its Debt to Equity has fluctuated over the past 5 years, first plummeted by 8324.85% in 2021, then skyrocketed by 19594.56% in 2025.
- Quarter analysis of 5 years shows Gain Therapeutics' Debt to Equity stood at $0.02 in 2021, then surged by 60.27% to $0.03 in 2022, then soared by 41.26% to $0.05 in 2023, then soared by 32.34% to $0.06 in 2024, then increased by 20.19% to $0.07 in 2025.
- Its Debt to Equity stands at $0.07 for Q3 2025, versus $0.12 for Q2 2025 and $0.07 for Q1 2025.